Eli Lilly stock

LLY · NYSE · USD

Compare Eli Lilly
$1,443.50Change from previous close: +1.14%Absolute change: +$16.22

Close · November 13, 2026

Price history

+41.12% over the period

1 year: from $1,022.87 (November 13, 2025) to $1,443.50 (November 13, 2026), +41.12%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$1,443.50
October 30, 2026$1,417.54
September 30, 2026$1,157.08
August 31, 2026$1,156.73
July 31, 2026$1,148.84
June 30, 2026$1,199.43
May 29, 2026$1,105.00
April 30, 2026$934.60
March 31, 2026$919.77
February 27, 2026$1,051.99
January 30, 2026$1,037.15
December 31, 2025$1,074.68
November 28, 2025$1,075.47
November 13, 2025$1,022.87

At a glance

  • The company

    Discovers, develops, manufactures and markets human pharmaceutical products for diabetes, obesity, oncology, immunology and neurology

  • Latest results

    Quarter to September 30, 2026 · EPS $7.48 (estimate $9.92)

TickerLandia's take on Eli Lilly

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$850.51
52-wk high$1,460.00

−1.13% from the 52-week high

Analysts · 31 analysts

Average target$1,463.40+1.38% vs. price

Buy 25 · Hold 4 · Sell 2 · Buy

TickerLandia Fingerprint: Eli Lilly

Compared with similar companies: very high profitability, very high price, and very strong momentum.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Eli Lilly is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Eli Lilly's P/E today is 62.9, above the median of its last 9 fiscal years (45.1; between 14.8 and 100.5 from 2016 to 2025). Eli Lilly's P/E (trailing 12 months): 46.9, +11% against the median of a group of 10 similar companies (42.3).

P/E compared with its history

Compared with 10 similar companies

Eli Lilly's metrics compared with similar companies
MetricEli LillyPosition in the groupBand
P/E (trailing 12 months)46.9Middle
Forward P/E28.5High
Operating margin51.3%High
ROE86.0%High
Debt/equity1.23Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Eli Lilly. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$24.4B

Latest quarter · Q3 2026

Net income

$6.45B

Latest quarter · Q3 2026

Quarterly net margin

26.4%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$1.29T
P/E
46.9
EPS
$30.81
Volume
1.87M
Daily trading
€3.67B
Dividend yield
0.48%
Last ex-dividend on November 13, 2026

How Eli Lilly is changing

All results
  • Revenue grew 21.6% a year on average over the last 5 years

  • Operating margin rose from 30.3% to 45.6%

  • Less cash than profit: free cash flow equal to 37% of net income

Returns

Eli Lilly returns with dividends

$1,000 invested in Eli Lilly 5 years ago, on November 15, 2021, would be worth $5,832 today with dividends reinvested: +483.19% in total, +42.35% per year. On price alone it would be $5,586 (+458.57%).

PeriodEli LillyS&P 500$1,000 becomes
1 month+23.75%−3.12%$1,237
6 months+42.11%+1.58%$1,421
Year to date+34.32%+10.46%$1,343
1 year+42.19%+12.23%$1,422
3 years+140.77%+71.41%$2,408
5 years+483.19%+61.48%$5,832
10 years+2,080.10%+249.40%$21,801

Over the last 6 months it has done better than 80% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Eli Lilly: technical analysis

Eli Lilly is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is at its highest close since January 2, 1990.

Trend
Upward
RSI (14 sessions)
70
Between 30 and 70
vs 200-session average
+30.12%

Support and resistance

Price areas where Eli Lilly has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$1,443.50
  3. Support$1,223.50−15.24%2 touches, last on September 30, 2026
  4. Support$1,173.11−18.73%2 touches, last on August 17, 2026
  5. Support$1,137.16−21.22%4 touches, last on October 8, 2026

Volatility and risk

Over the last year it has moved little with the S&P 500.

Beta (1 year) vs S&P 500
0.33
Volatility (60 sessions, annualised)
29.4%
Largest fall in the last year
−23.31%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Eli Lilly: seasonality

Average monthly price change over 37 years

+0.4%Jan−0.9%Feb+0.2%Mar+2.4%Apr+1.7%May+2.8%Jun−0.1%Jul+0.6%Aug+0.9%Sep+1.3%Oct+3.4%Nov+3.1%Dec

Over the last 37 years, the strongest month for Eli Lilly has been November: +3.40% on average, positive in 27 years out of 36. The weakest has been February: −0.89% on average, positive in 17 years out of 37.

Show chart data
MonthAverageMedianPositive years
January+0.40%−0.36%18 of 36
February−0.89%−1.26%17 of 37
March+0.25%+1.04%22 of 37
April+2.43%+1.61%22 of 37
May+1.66%−0.19%16 of 37
June+2.80%+3.43%24 of 37
July−0.10%+1.09%22 of 37
August+0.58%−0.98%16 of 37
September+0.93%+0.03%19 of 37
October+1.34%+1.05%21 of 37
November+3.40%+2.59%27 of 36
December+3.06%+1.05%20 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Eli Lilly and its competitors

Insulin brands Humalog and Humulin, together with the diabetes and obesity medicines Mounjaro, Trulicity and Zepbound, are among the best-known products of Eli Lilly and Company. The group also sells cancer treatments such as Verzenio, Jaypirca and Erbitux, immunology drugs including Taltz and Omvoh, and Kisubla for symptomatic Alzheimer's disease. Its prescription medicines reach customers in the United States, Europe, China, Japan and other markets worldwide, and the company works with partners such as Boehringer Ingelheim on the Jardiance family.

Headquarters
Indianapolis, United States
Employees
50,000
Founded
1876
Chief executive
David Ricks
Eli Lilly and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Eli LillyLLY$1.29T51.3%46.9+42.11%
Johnson & JohnsonJNJ$687.89B26.6%43.4+24.01%
AbbVieABBV$521.5B36.6%50.6+41.50%
Merck & Co.MRK$364.26B35.2%147.8+30.24%
AmgenAMGN$251.89B34.1%27.0+38.41%
Gilead SciencesGILD$208.48B38.2%—+26.33%

Same industry or related industries, similar size. Compare Eli Lilly with its competitors · Full profile